Weheal Inc., a medical device company funded and incubated by Baheal Pharma Group, with a focus on innovative cardiovascular disease technology, has unveiled its latest product - the 3rd-generation Heartpal ECG Device. Differentiated with existing 3-lead or 5-lead ECG devices primarily focuses on detecting cardiac arrhythmia, the advanced 3rd-generation wireless Heartpal ECG Device comes equipped with 12 leads and is designed for easy usability, enabling quick detection of serious heart conditions such as myocardial ischemia and myocardial infarction. This cutting-edge technology is capable of producing medical-grade electrocardiographs, thereby providing crucial time for medical interventions.

　 The 3rd-generation Heartpal ECG Device is renowned for its lightweight, portability, and user-friendly design, making it easily operable even by non-professionals at any time and place. Moreover, the one-touch feature enables instant connection with healthcare providers for ECG reading and online consultation services. Users can promptly receive expert clinical opinion from physicians, highlighting the key product features of ease of use, fast detection, and comprehensive functionality.

　 ”Ease of use” represents a simplified self-testing configuration. The integrated 12-lead Electrodes enables users to circumvent the complexities associated with traditional patch connections, making lead positioning and operation effortless, convenient for ECG self-test. "Fast Detection" represents immediacy, eliminating the need for external equipment or apps. With just a single touch, individuals can self-test, analyze results, and connect with a doctor online.
　 “Comprehensive functionality” Unlike single lead, 3-lead or 5-lead ECG devices on the market that can only monitor cardiac arrhythmia and irregular heartbeats, 12-lead wireless ECG device can not only detect arrhythmias but also pinpoint the location of ischemic myocardium, promptly detecting myocardial infarction. It offers comprehensive testing for disease such as arrhythmias, myocardial infarction, coronary disease, and structural heart disease, providing diagnostic value comparable to hospital electrocardiography equipment.

　 During testing, the 3rd-generation Wireless Heartpal ECG Device detects synchronous ECG signals, which are then accurately and stably translated using advanced algorithms.
　 The translated signals are recorded on a cloud platform and analyzed by remote health professionals. A health professional service team is available online 24 hours a day, effectively assisting individuals with high risk of cardiovascular events in detecting and mitigating their risks or receiving timely medical treatment. The increasing awareness of health and advancement in technology have prompted a growing interest in household medical devices as a crucial element in future family health management strategies. The 3rd-generation Wireless Heartpal ECG Device aims to exemplify the transition from medical technological innovation to tangible applications, enhancing the quality of life for general public. Hopefully the 3rd-generation Wireless Heartpal ECG Device can introduce more efficient and intelligent closed-loop solutions for monitoring cardiovascular disease, and can start a new trend in family health management.